Founder and CEO of PulmonaVat, specializing in lung organoid generation and tissue engineering. With master's and doctoral degrees in Biological and Biomedical Engineering from McGill University and inspired by her experience during the COVID-19 pandemic, she developed heterogeneous lung organoids that mimic the complexity of human lungs. Her work focuses on revolutionizing drug efficacy testing across diverse populations to prepare for future health crises. A recipient of honors like CONAHCYT and the Young Scientist Award from PETA, Alicia advocates for in-vitro models that reduce reliance on animal testing in personalized medicine and drug discovery.
